Biperiden Lactate

CHEMBL1201067 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
401.5 g/mol
LogP
Phase
4

The lactate salt of biperiden, often formulated for intramuscular or intravenous injection in emergency management of acute drug-induced dystonia or severe Parkinson's symptoms. It acts rapidly to relieve muscle spasm and involuntary movements. This injectable form is particularly useful when oral administration is not feasible.

分子量

401.5000 g/mol

TPSA

81.00 Ų

治療領域

作用機序

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(O)C(=O)O.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2

InChI

InChI=1S/C21H29NO.C3H6O3/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17;1-2(4)3(5)6/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2;2,4H,1H3,(H,5,6)

Molecular Formula

C24H35NO4

HBD / HBA

3 / 5

回転可能結合数

6

重原子数

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The lactate salt of biperiden, often formulated for intramuscular or intravenous injection in emergency management of acute drug-induced dystonia or severe Parkinson's symptoms. It acts rapidly to relieve muscle spasm and involuntary movements. This injectable form is particularly useful when oral administration is not feasible.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Biperiden Lactate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201067. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 197083. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.